Drug improves quality of life for Dobermanns with heart disease
22 Dec 2012
Veterinary scientists at the University of Liverpool have found that early screening and drug treatment for Dobermann dogs with a serious heart disease can extend and improve their quality of life.
The study, which took place over the course of six years with dogs in the UK, Canada and US, examined more than 70 Dobermanns with early signs of dilated cardiomyopathy (DCM).
The disease, which also affects cats and humans, causes the heart to become enlarged and death can be very sudden and unexpected if not detected in its early stages.
The cardiology team at the University's Small Animal Teaching Hospital examined whether early screening for DCM could improve the chances of longer survival with treatment of a drug called Pimobendan (Vetmedin).
''We have shown that screening dogs for DCM, and early treatment, can extend the life expectancy of Dobermanns with the condition and greatly enhance their quality of life''
They found that the drug slowed down the progression of the disease and prolonged good quality, symptom-free life by an average of an additional nine months.
